The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.80
Bid: 0.75
Ask: 0.85
Change: 0.00 (0.00%)
Spread: 0.10 (13.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.80
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Fevertree lowers guidance; DP Poland sales rise

Fri, 15th Jul 2022 11:21

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Ncondezi Energy Ltd, up 91% at 1.48 pence, 12-month range 0.004p-1.90p. The Mozambique-based power developer says it has launched a feasibility study for a 300 megawatt solar photovoltaic power plant and battery energy storage system. The study will require four months to be completed and will be funded through available capital after completing the restructuring of the Seritza term loan. The solar project will be located within the Ncondezi concession area, with three sites identified, and have an estimated pre-money net present value between USD60 million and USD65 million.

----------

N4 Pharma PLC, up 21% at 2.85 pence, 12-month range 2.02p-10.43p. In a pre-clinical study of delivery system Nuvec with TNF-alpha, known as Medicines Discovery Catapult, there is clear tumour suppression with 10 micrograms of TNF-alpha loaded into Nuvec, a lower dose than used in earlier studies. Biochemical analysis of blood and tissue samples show that treatment led to an increase in circulating plasma TNF-alpha levels. "We continue to make good progress in understanding how Nuvec can be used in the oncology space," says CEO Nigel Theobald.

----------

Novacyt SA, up 8.5% at 116.99 pence, 12-month range 1.06p-123.77p. The clinical diagnostics firm says its 'exsig' Covid-19 direct real-time PCR test has been approved in the UK under the the UK Health Security Agency's coronavirus test device approvals regulations. The test "removes the need for manual or automated extraction solutions to significantly improve laboratory workflow and reduce costs".

----------

DP Poland Ltd, up 6.9% at 6.20 pence, 12-month range 5.00p-9.00p. The franchise in Poland for Domino's Pizza said system sales were significantly above pre-Covid levels in June. The company saw like-for-like system sales increased by 24% compared to a year ago and by 23% compared to June 2019. Total system sales were up by 21% compared to June 2021 and 15% compared to June 2019. In the first 10 days of July, LFL system sales increased by 33% on a year before.

----------

AIM - LOSERS

----------

Fevertree Drinks PLC, down 27% at 869.50p, 12-month range 804.50p-2,871.00p. In the first half of 2022, the premium tonic water maker posts revenue of GBP160.9 million, up 14% from GBP141.8 million year-on-year. UK sales rise 6% to GBP53.5 million and US sales increase 11% to GBP40.1 million, while total Europe revenue jumps 27% to GBP52.4 million. However, Fevertree now expects earnings before interest, tax, depreciation and amortisation in a range of GBP37.5 million to GBP45 million, down from a prior range of GBP63 million to GBP66 million. In 2021, the company achieved Ebitda of GBP63.0 million. The company flags labour shortages in the US, resulting in greater UK production, which means greater exposure to increasing sea freight rates. In addition, glass availability has become "severely restricted" and industry-wide cost pressures, such as glass, have increased.

----------

Angle PLC, down 12% at 82.20 pence, 12-month range 71.70p-163.75p. The Surrey, England-based medical diagnostics company raises GBP20.1 million through the issue of 25.2 million shares via a placing, retail offer and subscription at a price of 80 pence per share, reflecting a 14% discount to Thursday's closing price at 93.50p. Net proceeds will be used to help its commercialisation plans for its Parsortix system. Now has 260.5 million shares issued overall.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
25 Apr 2024 11:56

N4 Pharma strikes partnership deal for intracellular delivery

(Alliance News) - N4 Pharma PLC on Thursday said it has entered into a collaboration agreement with SRI International Inc.

Read more
23 Apr 2024 13:32

IN BRIEF: N4 Pharma loss widens but "great optimism" remains

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of Nuvec - Posts revenue of GBP1,953 in 2023, compared to no revenue a year ago. Pretax loss widens to GBP1.4 million from GBP1.2 million. Looks ahead to the rest of 2024 with "great optimism."

Read more
18 Apr 2024 12:14

N4 Pharma sees potential in Nuvec delivery method for cancer treatment

(Alliance News) - N4 Pharma PLC on Thursday reported that its novel delivery system for cancer treatment has shown promise, after a successful trial.

Read more
15 Feb 2024 13:17

N4 Pharma shares jump on latest Nuvec developments

(Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

Read more
15 Feb 2024 12:06

IN BRIEF: N4 Pharma shares rise on "encouraging" Nuvec research

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - Reports an "encouraging" update from its Nuvec delivery system for cancer treatments, gene therapy and vaccines. It has completed in-vitro experiments combining epidermal growth factor receptor and polo like kinase 1 molecules onto a Nuvec nanoparticle, before testing it on lung cancer cells. "The work clearly shows that there is a strong beneficial effect at 48 hours on cellular inhibition compared to single dose siRNA, by combining both EGFR and PLK1 onto the same particle," N4 says.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
19 Jan 2024 13:00

N4 Pharma's Nuvec granted patent in India

(Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding the granting of its patent for Nuvec in India.

Read more
19 Jan 2024 09:26

IN BRIEF: N4 Pharma gets India patent for medical delivery system

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec - University of Queensland has informed the company that it has been notified by its Indian patent attorney of the granting of its patent for Nuvec in India. Nuvec is a novel silica nanoparticle delivery system for cancer treatments, gene therapy and vaccines. N4 Pharma says the granted patent in India is for a composition of matter patent for the particle itself, alongside the manufacturing process relating to how the particle is made. Says it matches the patents granted in the US, Canada, Europe, Japan, Australia and China.

Read more
16 Jan 2024 14:05

N4 Pharma subsidiary agrees work programme for glaucoma treatment

(Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for its ECP105 product, aimed at pre-clinical studies at King's College, London.

Read more
16 Jan 2024 13:26

IN BRIEF: N4 Pharma touts contract to test glaucoma treatment, ECP105

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company, focused on the development of Nuvec, a novel silica nanoparticle delivery system, for vaccines and therapeutics - Says subsidiary, Nanogenics Ltd, has signed a contract to start the formulation and sequence selection work to prepare its ECP105 product for testing in pre-clinical studies at King's College, London.

Read more
8 Jan 2024 12:30

N4 Pharma reports progress in Nuvec clinical research

(Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

Read more
8 Jan 2024 09:11

N4 Pharma hails increased efficacy of Nuvec when complexed with AAV8

(Alliance News) - N4 Pharma PLC on Monday said that a series of experiments have shown that Nuvec can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8.

Read more
18 Dec 2023 16:55

LONDON MARKET CLOSE: FTSE 100 outperforms European peers

(Alliance News) - Stock prices in London closed higher on Monday, after investors shrugged off hawkish comments from US Federal Reserve officials amid festive cheer.

Read more
18 Dec 2023 12:43

N4 Pharma rises on successful results from Nuvec administration

(Alliance News) - N4 Pharma PLC on Monday announced the successful oral administration of Nuvec with a DNA plasmid after receiving promising results from its research programme with the University of Queensland.

Read more
18 Dec 2023 11:17

N4 Pharma upbeat on recent Nuvec developments

(Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.